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SHORT REPORT

JOURNAL OF
NEUROINFLAMMATION

Open Access

Anti-lysophosphatidic acid antibodies improve
traumatic brain injury outcomes
Peter J Crack1*, Moses Zhang1, Maria Cristina Morganti-Kossmann2,3, Andrew J Morris4, Jonathan M Wojciak5,
Jonathan K Fleming5, Ila Karve1, David Wright6,7, Maithili Sashindranath8, Yona Goldshmit9,10, Alison Conquest9,11,
Maria Daglas8, Leigh A Johnston6,12, Robert L Medcalf8, Roger A Sabbadini5 and Alice Pébay9*

Abstract
Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in
neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective
in the mouse spinal cord following injury.
Findings: Here we investigated the use of this agent in treatment of secondary brain damage consequent to
traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls.
LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced
lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6
levels and improvement in functional outcomes.
Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular
LPA signaling to minimize secondary brain damage and neurological dysfunction.
Keywords: Lysophosphatidic acid, Traumatic brain injury, Human cerebrospinal fluid, Control cortical impact,
Magnetic resonance imaging, Anti-LPA antibody, IL-6

Findings
Traumatic brain injury (TBI) is a major cause of brain
neurotrauma, resulting in over 1.7 million brain injuries
annually in the United States. TBI commonly results
from motor vehicle accidents, falls, sports injuries or explosions, all of which disrupt normal brain function. The
primary injury can be focal or diffuse and initially produces hemorrhage and axonal injury followed by secondary effects such as edema and ischemia arising from
the activation of biochemical pathways including inflammation, cell death and gliosis [1]. These secondary-phase
effects begin immediately to widen the area of injury
and can persist for weeks to months, leading to profound behavioral deficits. Aggravated secondary brain
damage is also thought to impair the ability of resident
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neuronal stem cells to regenerate the lost neurons.
There are no FDA-approved drugs specific for TBI treatment and medical intervention is limited to supportive
care. Thus, the ideal therapy for TBI would have the
combined effects of reducing the initial injury as well as
limiting the secondary inflammatory responses while
simultaneously promoting regeneration and replacement
of lost neural tissue.
Lysophosphatidic acid (LPA) is a bioactive, proinflammatory lysophospholipid found in the extracellular compartment, such as in blood and cerebrospinal
fluid (CSF). LPA mainly acts through binding to its specific G-protein-coupled receptors LPA1–7 to induce
pleiotropic effects on multiple cell types [2]. LPA is an
inflammatory mediator, released by activated platelets,
astrocytes and other pro-inflammatory cells. In the nervous system, although the role of LPA signaling in development has been described in detail, recent data also
suggest an involvement of LPA in neurotrauma [2].
This is corroborated by compelling evidence from our
group showing upregulation of LPA receptors following
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central nervous system (CNS) neurotrauma [3,4]. Using
post-mortem human brains of normal individuals and
patients who died following acute closed-head injury,
we demonstrated that low constitutive expression levels
of LPA receptors detected in normal human brain were
upregulated following TBI. Interestingly, the upregulated expression of LPA1 co-localized with astrocytes
while LPA2 was upregulated on the ependymal cell
layer of the lateral ventricles [3]. Furthermore, using a
mouse hemi-section model of spinal cord injury (SCI),
we recently demonstrated that LPA is causally involved
in the outcome of injury in that blocking its signaling
via treatment with the specific anti-LPA monoclonal
antibody (mAb), B3, limited glial scar formation, improved neuronal survival, promoted neurite sprouting
and improved motor function [5]. We also observed
that injection of LPA in vivo stimulated the inflammatory response and proliferation of glial cells in the Zebrafish following SCI [5]. In vitro studies also demonstrated
the ability of the anti-LPA mAb to block receptor signaling in cells over-expressing LPA1–3 receptors [5].
Here, we report for the first time that LPA levels increase significantly in CSF samples taken from TBI patients as well as from mice subjected to control cortical
impact (CCI) injury. Moreover, blocking LPA with the
specific murine anti-LPA mAb, B3, improved neurological outcomes in the CCI mice. This study provides
the first evidence that therapeutic anti-LPA mAbs could
be useful in treating TBI-associated secondary damage.
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Table 1 Demographic information for patients with
severe traumatic brain injury
Patient

Age Sex Oxygen saturation Injury* GCS ISS

GOSE

1

23

M

Normoxic

4

7

33

4

2

19

M

Normoxic

1

8

30

5

3

50

M

Hypoxic

1

5

41

4

4

33

M

Normoxic

4

4

38

1

5

40

M

Normoxic

6

7

21

6

6

33

M

Hypoxic

2

3

43

4

7

21

F

Normoxic

1

7

21

3

8

26

F

Hypoxic

6

3

45

3

9

22

M

Normoxic

5

7

30

5

10

35

M

Hypoxic

6

4

45

5

11

25

M

Hypoxic

1

4

41

N.A.

12

47

M

Normoxic

4

7

29

3

13

26

M

Normoxic

1

8

34

14

29

F

Hypoxic

1

5

38

15

20

M

Normoxic

4

3

21

3

16

48

F

Hypoxic

8

3

34

1

17

22

M

Normoxic

1

8

34

18

24

M

Hypoxic

1

3

34

19

19

M

N.A.

N.A.

N.A. N.A. N.A.

20

31

M

Hypoxic

1

5

21

39

M

Normoxic

6

7

26

8

22

25

F

Hypoxic

1

3

35

3

23

52

F

Normoxic

4

6

43

1

Methods

24

36

M

Normoxic

4

3

29

3

Ethics

25

58

M

Normoxic

3

7

50

5

26

25

M

Normoxic

6

8

17

1

Control 1 42

M

Normoxic

Control 2 80

M

Normoxic

Control 3 56

M

Normoxic

All experimental work performed in this study was approved by the Human or Animal Research Ethics committees of the University of Melbourne (HREC1136323,
AEC0911437) or the Alfred Hospital (HREC194/05), in
accordance with the requirements of the NHMRC.
Animals

Eight-week-old male C57BL/6 J mice (23 ± 3 g) were
intravenously administered, in a blinded fashion, a single
dose of either murine IgG2β mAb targeted to LPA (B3,
25 mg/kg) [5] or an IgG2β isotype-matched mAb
(25 mg/kg) either 1 h prior to, or 30 minutes post TBI.
Injured mice were compared with uninjured sham controls. At all times, the investigator was blinded to the nature of the drugs to be delivered. Decoding of the
samples was only performed once data were quantified.
CSF measurement

Human CSF was obtained from patients with TBI admitted to the Alfred hospital with delayed informed consent
obtained from the next of kin (Table 1). The inclusion
criteria for the patients required that they had severe

43

5

5

2

*Mechanism of iInjury: 1, motor vehicle accident; 2, motor bicycle accident;
3, pedal cyclist; 4. pedestrian; 5, penetrating injury; 6, fall/jump; 8, other;
Glasgow Coma Scale (GCS) ≤8: severe; 9–12: moderate; ≥13: minor. ISS, injury
severity score: 0, no injury; 75, maximal untreatable injury; GOSE, extended
Glasgow outcome scale: 1, death; 2, vegetative state; 3, severe disability
(lower band); 4, severe disability (upper band); 5, moderate disability (lower
band); 6, moderate disability (upper band); 7, good recovery (lower band);
8, good recovery (upper band); M, male; F, female. N.A., not available.

TBI with a post-resuscitation Glasgow Coma Scale
(GCS) ≤8 (except one patient with GCS = 10) who rapidly deteriorated, requiring an extraventricular drain device (EVD) to monitor intracranial pressure (ICP) and
therapeutic drainage of CSF [6]. Patient management included computed tomography (CT) scans within 4 h
from TBI, followed by surgical implantation of an EVD.
CSF was drained when the ICP exceeded 20 mmHg, and
was collected daily beginning from the day of admission
(day 0) up to day 5 after injury. Exclusion criteria were
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pregnancy, neurodegenerative diseases, HIV and other
chronic infection/inflammatory diseases, or history of
TBI. Clinical parameters were recorded by paramedics
and medical staff, including GCS, hypotension (systolic
blood pressure <90 mmHg) and occurrence of prehospital hypoxia. Patients were allocated to the hypoxic
cohort (SaO2 < 92% or apnoeic or cyanotic at the field of
the accident) or normoxic cohort (normal SaO2) [7].
TBI was classified into focal brain injury or diffuse brain
injury following the Marshall CT score [8] as described
[6]. The injury severity score (ISS) was assessed by including extracranial trauma [9]. The extended Glasgow
outcome scale (GOSE) was assessed at 6 months post
admission as described [6]. Control CSF samples were
obtained from hydrocephalus patients undergoing implantation of ventriculo-peritoneal shunts with exclusion
criteria similar to the TBI cohort.
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operated in negative electrospray ionization mode with
optimal ion source settings determined using a series of
synthetic LPA species. The ion source settings were a
declustering potential of 61 V, entrance potential of
10 V, collision energy of 23 V, collision cell exit potential
of 16 V, curtain gas of 20 psi, ion spray voltage of
5,500 V, ion source gas1/gas2 of 40 psi, and temperature
of 550°C. MRM transitions corresponding to 15 indicated abundant LPA molecular species and the C17
LPA internal standard were monitored. Quantitation
was accomplished by correction for recovery of the
C17 LPA internal standard with reference to calibration curves generated using authentic LPA standards
(Avanti Polar Lipids) that were quantitated separately
by phosphorous analysis after wet digestion in perchloric acid.
Model of controlled cortical contusion in mice

Liquid chromatography-mass spectrometry
(LC-MS) methods

Levels of LPA were measured by high-performance liquid chromatography-electrospray ionization-tandem
mass spectrometry as described previously [10]. Briefly,
lipids were extracted from CSF samples using acidified
organic solvents. Sample 10 to 50 mL was combined
with 0.1 M HCL to a final volume of 0.5 mL in an 8-mL
borosilicate glass tube containing 1 mL CHCl3 and 2 mL
MeOH and 50 pmol of 1- hetpadecanoyl 2 hydroxy glycerol 3-phosphate (C17-LPA: Avanti Polar Lipids,
Albaster, AL, USA). The tube was capped, vortexed and
an additional 1 mL of CHCl3 and 1.3 mL 0.1 M HCl
added. The tube was vortexed again and centrifuged (500
× g for 5 minutes) to separate the upper and lower phases.
The lipid containing the lower phase was removed with a
Pasteur pipette to a 4-mL borosilicate glass vial and evaporated to dryness under N2 gas using a Zymark Turbovap.
The dried samples were resuspended in 0.1 mL MeOH
and transferred to autosampler vials.
Lipids were analyzed using a Shimadzu UFLC coupled
with an ABI 4000-Qtrap hybrid linear ion trap triple
quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode. Lipids were separated
using an Agilent Zorbax Eclipse XDB C8 column, 5-μm,
4.6 × 150 mm column. The mobile phase consisted of
75/25 of methanol/water with formic acid (0.5%) and
5 mM ammonium formate (0.1%) as solvent A and 99/1
of methanol/water with formic acid (0.5%) and 5 mM
ammonium formate (0.1%) as solvent B. Separation was
achieved using a gradient of 0% B for 1 minute, 0% B to
100% B in the next 1 minute, maintained at 100% B for
the next 10 minutes, and equilibrated to the initial conditions in 3 minutes. The flow rate was 0.5 mL/minute
with a column temperature of 30°C. The sample injection volume was 10 μL. The mass spectrometer was

Mice were subjected to CCI as described by Dixon et al.
[11] in rats. Mice were anesthetized for 5 to 10 s with
gaseous isoflurane (1 mL/minute), followed by an intraperitoneal injection of ketamine (100 mg/kg, Parnell)/
xylazine (10 mg/kg, Parnell). A sagittal scalp incision
was made to expose the underlying parietal bone and a
2-mm burr hole was drilled using a Dremel 10.8 V drill
with a 0.8 mm tip (Dremel, Europe) into the skull above
the right parietal cortex, 1.5 mm posterior to the Bregma
area and 2.5 mm lateral to the midline. The rounded
section of bone was removed to expose the underlying
cortex. Mice were placed on a stereotaxic frame and a
1.5-mm-deep impact was made into the brain on the exposed cortex using a computer-controlled impactor, with
the center at coordinates anteroposterior = − 2.0, and
mediolateral = + 2.0 from the Bregma area. The following parameters were set onto the program linked to the
rounded tip impactor (LinMot-Talk 1100, Spreitenbach
Switzerland): withdrawal of the tip 20 mm away from
resting position at 1 m/s, impact at a velocity of 5 m/s
and depth of 1.5 mm, interval of 100 ms and withdrawal
of the tip 1.5 mm towards the resting position at 1 m/s.
Following the impact, the removed bone section was
placed back onto the skull, with a small amount of paraffin to close up the brain. The incision was closed up
with a silk 5.0 metric suture (Syneture Tyco Healthcare,
Dublin, Ireland). Mice were given Buprenorphine intraperitoneally (0.6 mg/kg, Reckitt Benckiser Healthcare)
and placed on a heat mat for post-surgical recovery.
Sham controls underwent anesthesia, scalp incision and
bone removal, but no injury, and then were sutured,
given analgesic and put on a heat blanket for recovery.
Mouse CSF sampling

CSF sampling from the cisterna magna of the mouse
was carried out in a cohort of mice that had undergone
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TBI. Mice were anesthetised with an intraperitoneal injection of ketamine and xylazine and the head placed in
a stereotaxic frame. After initial skin incision the subcutaneous tissue and muscles (m. biventer cervicis and
m. rectus capitis dorsalis major) were separated by blunt
dissection with forceps and a pair of microretractors was
used to hold the muscles apart. Using a dissecting
microscope the dura mater of the cisterna magna was
punctured by a glass capillary tube and approximately
10 μL of CSF was extracted by capillary action and immediately frozen in liquid nitrogen for analysis.
Behavioral analysis

Neurological function post TBI (at 48 h) was assessed
using DigiGait™ v 11.5 (Mouse Specifics Inc., Quincy,
MA, USA) apparatus as described in [12]. Mice were
run on a transparent treadmill at a speed of 15 cm/s
both before injury and post injury for 5 s. Videos of paw
placement were captured in the ventral plane by the
DigiGait™ software and analyzed by the software. All surgery and behavioral analyses for antibody-treated mice
were performed in a blinded fashion. Gait measurements
were calculated as post to pre-injury ratios of sham versus trauma mice. All gait parameters for antibodytreated mice were presented as fold change to trauma
values. Statistical significance was determined by the
Student t-test (unpaired, two-tailed) while comparing
the raw data in each cohort, although the data have been
depicted as fold-change relative to TBI.
Magnetic resonance imaging (MRI)

Mice were intravenously injected with IgG isotype control (25 mg/kg) or LPA antibody (25 mg/kg) 30 minutes
post TBI, and imaged both 1 day and 7 days after TBI.
MRI scans were performed using a Bruker 4.7 Tesla
small animal MRI scanner (Florey Institute of Neuroscience and Mental Health) to quantify the progression of
tissue damage and the subsequent repair. Mice were initially anesthetized with approximately 3% isoflurane in a
1:1 mixture of medical-grade air and oxygen. Anesthesia
was maintained throughout scanning with 0.25 to 1.5% isoflurane through a nosecone placed over the animal’s snout
and respiration was continuously monitored throughout
the experiment with a pressure-sensitive probe positioned
under the animal’s diaphragm. Anesthetized animals were
laid supine on a purpose-built small-animal holder and
their heads fixed into position with ear and bite bars. A
surface receiver coil was placed over the animals’ heads
and the cradle was inserted into a transmitter coil fixed
inside a BGA12S-HP gradient set for imaging. To accurately assess lesion size, groups of eight mice from
each treatment were used. The MRI protocol consisted of
a 3-plane localizer sequence followed by multi-echo T2
and diffusion-weighted sequences. The total scanning time
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was kept to less than 2 h per animal. Multi-echo T2weighted images were acquired using a rapid acquisition, relaxation enhanced (RARE) sequence with RARE
factor = 2; repetition time = 2,500 ms; effective echo
time (TEeff ) = 10, 30, 50, 70, 90 and 110 ms; field of
view (FOV) = 1.6 × 1.6 cm2; matrix = 192 × 192; and 16
slices with thickness = 0.5 mm. The diffusion-weighted
images were acquired with a diffusion-weighted echoplanar imaging (DWI-EPI) sequence with TR = 7.5 s;
TE = 32.74 ms; repetitions = 3; FOV = 1.6 × 1.6 cm2;
matrix = 64 × 64; 28 slices with thickness = 250 μm; 126
diffusion directions with diffusion gradient duration
(δ) = 3 ms, diffusion gradient separation (Δ) = 14 ms
and b-value = 1,200 s/mm2. Mean diffusivity maps were
derived from the diffusion-weighted data. TBI-affected
regions were manually outlined by a blinded operator
on both T2 weighted and diffusion-weighted images
using ImageJ software (NIH) and volumetric analysis
carried out using Matlab (MathWorks, Natick, MA,
USA).

Histology and brain injury volume analysis

Brains were cut into 10-μm coronal sections starting at
the rostral end, paraffin-embedded and mounted onto
glass slides. Every tenth slide was stained with H&E.
Photomicrographs were captured using a Zeiss Axioskop
microscope and lesion area was determined using the
Image J software (v1.47; NIH). Tissue swelling in the injured side was accounted for by dividing the lesion area
from each section by the ratio of the areas of the injured
relative to uninjuredside. The Cavalieri formula was used
to calculate total lesion volume as follows:
Volume ¼ ΣA  t  ISF
where A = sum of the corrected lesion areas; t = section
thickness (10 μm) and ISF = inverse of the sampling
fraction (1 in 10 sections was counted, that is, sampling fraction = 1/10). Lesion volume values were analyzed using the unpaired Student t-test, with a value of
P <0.05 considered statistically significant.

Cytokine measurements

ELISA kits (BD Biosciences, USA) were used to detect
mIL-6 (kit # 555240), mTNF-α (kit # 560478) and mIL1β (kit# 559603) levels in brain tissues as per manufacturer guidelines: 100 μg protein extract was loaded per
well, with experiments conducted in duplicate. Protein
concentrations of individual samples were determined
using a linear standard curve of IL-6, TNF-α or IL-1β
standards (4–200 pg/mL).
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Antibody-LPA binding measurements

B3 binding to individual LPA species was measured
with the Kinetic Exclusion Assay (KinExA, Sapidyne
Instruments, Boise, ID, USA) using a KinExA 3200
equipped with an autosampler. The LPA conjugate used
to capture the free antibody was prepared by crosslinking 1-(12-mercaptododecanoyl)-2-hydroxy-/sn/-glycero-3phosphate to maleimide-activated BSA (Thermo Scientific,
Waltham, MA, USA) in 0.1 M sodium phosphate, 0.15 M
NaCl, pH 7.2. The purified LPA-BSA conjugate was diluted
with running buffer (PBS without calcium and magnesium
(Cellgro, Manassas, VA, USA) with 0.002% azide), absorbed
to PMMA beads (Sapidyne Instruments, Boise, ID, USA)
and blocked with Fraction V fatty acid-free BSA (FAF-BSA,
Calbiochem, USA). The 16:0, 18:0, 18:1, 20:4 acyl LPA species (Avanti Polar Lipids) and 18:2 acyl LPA (Echelon
Bioscience, Salt Lake City, UT, USA) were weighed
out in amber glass vials and dissolved in 100% methanol by repeated sonication and vortex mixing as
needed until the solutions were clear. Aliquots (1 to
3 μmol) were transferred to new amber glass vials,
and the methanol was evaporated using a dry argon
stream. The dried LPA aliquots were resuspended in
running buffer containing 1 mg/mL FAF-BSA by repeated sonication and vortex mixing to a final LPA
concentration of 0.5 mM.
Samples containing 10 μM of each LPA species
(100 μM 18:0 LPA), 1 nM B3 antibody and 3 μM FAFBSA in the KinExA running buffer were prepared in silanized glass tubes. Using a glass syringe, 1 mL of each
sample was transferred to a glass tube containing 2 mL
of a receptor solution (1 nM B3, 3 μM FAF-BSA in running buffer) and gently mixed. This 3-fold serial dilution was repeated until 14 sample fractions were
prepared for each LPA species. Sample fractions were
equilibrated for >1 h at room temperature prior to performing equilibrium affinity experiments. B3 captured
on the beads was detected using a DyLight sheep antimouse heavy and light chain secondary (Jackson ImmunoResearch, West Grove, PA, USA) at 375 ng/mL in
running buffer. Each fraction was analyzed in duplicate
using the KinExA Pro software version 3.6.3 (Sapidyne
Instruments, Boise, ID, USA).

Results
LPA levels are elevated in human and mouse CSF
following TBI

Our previous work showed that LPA receptors were upregulated following brain trauma in mice and humans
[3,4]. Although these key components of the LPA signaling pathway were upregulated, the levels of LPA were
not assessed after injury. Consequently, we report here
for the first time, elevated levels of total LPA in human
CSF obtained from patients with TBI compared to non-
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injured control individuals (Figure 1A-B). In TBI patients, levels of LPA in the CSF were substantially and
significantly increased from 0.050 ± 0.007 μM in control
samples to 0.270 ± 0.050 μM in the first 24 h and
returned to basal levels by 120 h (0.059 ± 0.014 μM),
showing that the LPA-pulse usually occurs within the
first 24 h after injury (Figure 1A). Figure 1B depicts the
distribution of LPA isoforms in the human CSF showing
that 16:0 and 18:0 LPA are the predominant isoforms
contributing to the total LPA pulse. These data thus suggest that LPA production and/or degradation in CSF
may be dysregulated/upregulated early in the injury
process.
Before testing the therapeutic value of our anti-LPA
mAbs in a mouse model of TBI, we first sought to corroborate the human findings as to whether LPA levels
were also upregulated in the CSF of injured mice. We
employed the CCI model of TBI as this closely reproduces the closed TBI of our patient population [13]. As
shown in Figure 1C, total LPA levels increased in the
CSF of CCI-injured mice 3 h post TBI, returning to
baseline levels at 14 h post injury. A comparison of
Figures 1A versus 1C reinforces the similarity of our
findings between the CCI model and human TBI, as
both displayed dysregulation of LPA in the early hours
post injury. We also performed lipidomics analysis to
determine the isoform distribution of LPA species in
the CSF after injury. Interestingly, Figure 1D shows
that 18:0 LPA is by far the predominant LPA species
contributing to the LPA-pulse produced by the injured
mouse brain.
Anti-LPA mAbs reduce the lesion size following TBI

Having demonstrated the upregulation of the LPA target
in the CCI model (Figure 1C-D), it was important to
demonstrate a causal connection between elevated LPA
levels in the brain and the progression of secondary tissue injury. Accordingly, we assessed the ability of a specific anti-LPA mAb (B3/Lpathomab), to block the
pathological actions of LPA in CCI mice. We had previously shown potency of this antibody in blocking LPA
receptor signaling as well as the specificity of this antibody towards LPA [5]. We adapted a CCI model originally described in the rat, which shows a high survival
rate but no chronic neurological impairment [11]. In our
model of CCI, the impactor only travels to 1.5 mm of
depth within the brain, resulting in a mild cortical
lesion.
In our study, mice received B3 or an isotype-matched
control mAb (25 mg/kg) in a double-blinded manner
given intravenously by tail-vein injection 1 h prior or
30 minutes post TBI and were sacrificed 48 h later, for
lesion measurement. As shown in Figure 2, B3 treatment
reduced the hemorrhage normally observed following
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A

B
[LPA species] (µM)

[Total LPA] (µM)

0.4

**

0.3
0.2
0.1
0.0

0.10

**

0.05

*
0.00

control

<24

>120

16:0

Hours Post-Injury

18:1

18:2

20:4

D

3

[LPA species] (µM)

[Total LPA] (µM)

C

18:0

Individual LPA species

*
2

1

0

2.5

*

2.0
1.5
1.0
0.5

*

0.0
sham

3

14

Hours Post-Injury

16:0

18:0

18:1

18:2

20:4

Individual LPA species

Figure 1 Cerebrospinal fluid (CSF) analysis of lysophosphatidic acid (LPA) content following traumatic brain injury (TBI). Total (A) and
individual (B) LPA levels (means ± standard error of the mean (SEM)) in the CSF of patients with non-penetrating TBI at different time points
(control, n = 3; <24 h, n = 18; >120 hours, n = 11). (F(2,29) = 6.453, P = 0.005 (one-way analysis of variance (ANOVA)); Tukey multiple comparisons
tests: <24 h versus >120 h (Total), **P = 0.007; <24 h versus >120 h (18:0), **P = 0.008; <24 h versus >120 h (20:4), **P = 0.04. Total (C) and individual
(D) LPA levels (means ± SEM) in the CSF of mice post control cortical impact (CCI) at different time points (sham, n = 4; 3 h, n = 6; 14 h, n = 6).
(F(2,13) = 6.674, P = 0.01) by one-way ANOVA; Tukey multiple comparisons test: 3 h versus sham (Total), *P = 0.02 and 3 h versus 14 h (Total), *P = 0.03;
3 h versus sham (18:0), *P = 0.01 and 3 h versus 14 h (18:0), *P = 0.03; 3 h versus sham (18:2), *P = 0.03 and 3 h versus 14 h (18:2), *P = 0.01.

CCI. These data show that compared to isotype control,
B3 significantly reduced the subdural hematoma and the
lesion area (Figure 2A, B respectively). Compared to
controls, brain lesion volume also decreased significantly
by 25.5 ± 2.7% (Figure 2C, n = 6) when mice were treated
with B3 60 minutes prior to injury. Importantly, a single
dose of B3 administered 30 minutes after TBI resulted
in a 36.4 ± 6.4% reduction in lesion volume in B3 treatment compared to control (Figure 2D, n ≥7).
MRI scans were also used to assess lesion size and diffusion characteristics over a temporal profile (Figure 2E-H).
Animals received a single tail-vein administration of B3 or
isotype control 30 minutes after TBI and were then imaged by MRI on days 1 and 7. We observed a reduction of
lesion volume in all animals after 7 days when compared to day 1. Importantly, B3 treatment further reduced the lesion volume, with a statistically significant
difference observed at 7 days as delineated on the T2
maps and at 1 and 7 days as delineated on the mean
diffusivity maps. The mean diffusivity maps show a significance decrease in edema in the B3-treated group at
both day 1 and day 7 compared to mice receiving
isotype-matched mAb control. This finding is mirrored
in the T2 maps with a trend at day 1 and significance
seen at day 7. Together, these data demonstrate that

anti-LPA treatment reduces the lesion size of TBI and
accompanying edema.
Anti-LPA treatment improves behavioral deficits after TBI

The DigiGait system and software were used to assess
changes in neurological function in mice after TBI. We
established that injured mice displayed impairments in
motor functions in their left hind and fore limbs (contralateral limbs to brain injury side) compared to sham
mice in parameters such as stance/swing ratio, % swing
in stride, stance and stride frequency (data not shown).
All gait indices calculated for the B3- and isotype
control-treated mice are presented as fold-change to
TBI. Importantly, the administration of B3, 30 minutes
post TBI significantly improved behavioral outcomes of
the parameters of stance, stride length and stride frequency (Figure 3A-C) and there was a trend to significance in step angle, however this was not statistically
significant (Figure 3D). These results indicate that B3
treatment post TBI led to improvements in neurological
function after TBI. This long-term behavioral benefit in
addition to the acute improvements in injured brain volume seen in Figure 2, suggests that anti-LPA antibodies
have neuroprotective properties in attenuating both the
immediate and secondary phases of brain injury.
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Figure 2 B3 significantly reduces lesion volume and diffusion following traumatic brain injury (TBI). (A, B) Representative images of
mouse brains 2 days following TBI, isotype control (A) or B3 (B) received 30 minutes post injury, showing extent of hemorrhage. (C, D)
Representative quantification of injury volume 2 days following TBI after Nissl 2 staining, with treatment received 1 hour pre-TBI (C) or 30 minutes
post-TBI (D); means ± standard error of the mean (SEM), n >7 animals; *P <0.05, **P <0.01 by two-tailed t-test. (E) Representative T2 maps of
mouse brain 1 and 7 days following TBI in control animals (isotope) or animals treated with B3 (antibody), both given at 25 mg/kg, 30 minutes
post injury, by tail-vein injection. (F) Representative mean diffusivity map following the same protocol. (G) Quantification of infarct volume using
T2 maps and (H) mean diffusivity maps in isotype controls (TBI) and B3-treated animals (TBI + lysophosphatidic acid (LPA) antibody). Data are
means ± SEM, n = 8 animals; *P <0.05 by t-test.

Anti-LPA treatment decreases IL-6 after TBI

We assessed whether or not anti-LPA mAb treatment
could have an anti-inflammatory action by examining
the expression levels of key inflammatory cytokine
known to contribute to the secondary phases of neurotrauma. For example, IL-6 and IL-1β are important cytokines with levels that correlate with poor outcomes and
behavioral defects, and it has been suggested that preventing IL-6 and IL-1β upregulation could have therapeutic benefit in TBI [14]. As expected in our model of
CCI we observed a rapid (4 h) upregulation of IL-6 protein concentration following TBI, in both hemispheres

(Figure 4). Interestingly, the ELISA data showed a statistically significant decrease in IL-6 protein levels after
treatment with B3 at both 4 and 24 h after TBI when
compared to the isotype control (Figure 4A). Importantly, levels of IL-6 observed in the presence of B3 at
both time points were not statistically different from the
levels observed in sham (Figure 4A). However, unlike IL6, the levels of IL-1β and TNFα were not altered after
B3 treatment. The dramatic effect of anti-LPA mAb
treatment in reducing IL-6 production suggests that the
structural and functional improvement achieved with
antibody treatment involved LPA-mediated induction of
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Figure 3 B3 treatment post TBI significantly improves behavioral outcome. At 48 h after traumatic brain injury (TBI), mice treated with B3
display improvement in the left hind limb parameters of stance (A), stride length (B), stride frequency (C) and step angle (D). B3 and isotype
control values are presented as fold-change to TBI. Data represent mean ± standard error of the mean (SEM), *P <0.05, n = 10 animals per group.

IL-6. Moreover, the data corroborate a role of LPA in
enhancing the inflammatory process that follows TBI
and raises the possibility that LPA might modulate the
production of key inflammatory cytokines, such as IL-6,
following neurotrauma.

Discussion
Currently, there are no Food and Drug Administration
(FDA)-approved drugs specifically developed for the
treatment of TBI. The high frequency of morbidity and
mortality in these patients is attributed to the lack of
therapeutic agents that address the mechanisms involved
in brain injury. Here, we provide evidence for a role of
the pro-inflammatory bioactive lipid LPA, in contributing to TBI neurotrauma by demonstrating the efficacy of
our anti-LPA mAbs to mitigate early effects of injury
such as hemorrhage, edema and injured brain volume as
well as mitigating the longer-term behavioral deficits.
It is likely that the reduced secondary effects mediated
by anti-LPA treatment are due to the ability of the antibody to block LPA-induced release of inflammatory cytokines, particularly IL-6. Upregulation of IL-6 in the
brain is considered to be a main driver of the inflammatory response after TBI [15] and contributes to the
behavioral deficits, as demonstrated by the ability of
anti-IL-6 antibody treatment to mitigate brain injury
and behavioral responses in the mouse model of TBI
and hypoxia [15]. This is consistent with the association

between elevated serum levels of IL-6 and poor outcomes in TBI patients [16,17].
Importantly, our study is also the first to demonstrate
that the LPA levels are dysregulated in the CSF as a consequence of brain injury in humans as well as in mice. It
appears that the LPA-pulse occurs in the early, primary
phase of brain injury, as we observed a marked increase
as early as 4 h post injury in the mouse CCI model and
within 24 h in TBI patients. This suggests that LPA may
be one of the first players in response to injury and that
it could contribute to both primary and secondary sequelae of events. Presumably, the LPA-pulse was modified by our anti-LPA mAb treatment such that the
neurotoxic and pro-inflammatory effects of LPA on
brain IL-6 levels were reduced. Both CSF and plasma are
known to contain one of the major enzymes involved in
LPA production, autotaxin, as well as its lysophospholipid substrates [18-20]. The beneficial effects of our antibody therapy in reducing hemorrhage and edema can be
explained by the ability of LPA to enhance the permeability of the blood brain barrier (BBB) in vivo [21]. It is
thus possible that the dysregulated LPA observed following TBI contributes to an increase permeability of the
BBB, an effect that could thus potentially be blocked by
anti-LPA mAb treatment.
Our most compelling evidence for a causative role of
LPA in murine TBI comes from studies using a specific
murine mAb against LPA, B3. A single intravenous
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Figure 4 B3 significantly reduces IL-6 production comparable
with sham levels but not IL1-β and TNF-α following traumatic
brain injury (TBI). The graphs show the levels of cytokines in the
ipsilateral hemisphere of mouse brains at 4 and 24 h following TBI.
(A) Il-6. (B) IL-1β (C) TNF-α. Animals received a single intravenous
injection of B3 (25 mg/kg) or its isotype control (Ab isotype), 30
minutes post injury. Data are mean ± standard error of the mean of
triplicates. Statistical significance of B3 treatment was detected by
one way analysis of variance followed by Bonferroni post hoc
analysis, *P <0.05; significance of cytokine levels as a consequence of
TBI injury is indicated by #P <0.05.

administration given 30 minutes after injury to CCI mice
was able to significantly and substantially reduce the lesion size as assessed both histologically and by T2weighted MRI. This neuroimaging technique is employed
routinely in clinical settings to characterize the extent of
brain injury and measure ensuing edema.
The observed near-term neuroprotective effects of the
anti-LPA mAb can be explained by the well-known
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effects of LPA in inducing necrosis in cultured neurons,
promoting neurite retraction and preventing neuronal
differentiation and development (reviewed in [2]), effects
that are, in part, reversed by antibody treatment. These
neuroprotective actions seen in the TBI model corroborate our previous studies showing upregulation of LPA
receptors in the injured mouse spinal cord and human
brain [3,4] and that blocking LPA signaling with B3 improves outcome in mice subjected to SCI [5].
The potent efficacy of the anti-LPA mAb in mitigating
trauma in the murine CCI model, together with the fact
that LPA levels were also dysregulated in the mouse CSF
following TBI, indicate that the findings from this model
may translate well into human TBI therapies and that
our humanized variant of the anti-LPA mAb could be a
novel treatment for the condition. Neutralizing extracellular LPA signaling could be the first therapeutic agent
to mitigate both primary and secondary phases of neurotrauma, with resulting potential beneficial outcomes in
rehabilitation and functional recovery for the patients. A
variety of therapeutic interventions in the LPA signaling
pathway could be envisioned and have been discussed
previously [2]. One could develop small molecule inhibitors targeting either the LPA receptors or key enzymes
in the biosynthetic machinery responsible for LPA production. Regarding LPA receptor antagonists, there is
the problem that there are six G protein-coupled receptors (GPCRs) for LPA plus two purinergic receptors and
possibly one ion channel (transient receptor potential
cation channel subfamily V member 1 (TRPV1)) This receptor redundancy may require the development of a
pan-LPA receptor antagonist, as there are several LPA
receptors expressed in the human brain after neurotrauma [3]. This would pose a hurdle for medicinal
chemistry. Alternately, one could target the upstream
biosynthetic machinery responsible for LPA upregulation
in the CNS. Although autotaxin (ATX) is a major source
of LPA in the blood and some tissue, it may not be the
source of dysregulated LPA after neurotrauma and future work will be needed to determine the role of LPA
production including phospholipase (PLA)1, PLA2, alpha
glycerol kinase (AGK) and other monoacylglycerol
(MAG)-kinases as well as glycerol-3-phosphate acyltransferase (GPAT). Lysophosphatidyl choline (LPC), the
substrate for LPA production by ATX, is very low in human CSF even after TBI (50 nM) and is consistent with
previous reports of low LPC in normal CSF [22], and we
would argue that ATX may not be the key enzyme responsible for LPA production. However, further experiments are planned to determine the source of the LPA.
It is interesting to note that the LPA profile (Figure 1)
suggests that the brain produces a pattern of LPA species quite distinct from plasma. LPA 18:0 is overwhelmingly the predominant species in the injured mouse CSF.
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The 18:0 is also a major LPA isoform in the injured human CSF but 16:0 also appears to be predominant. It is
interesting to note that these species are not the most
abundant in plasma. This needs to be confirmed in more
detailed studies that are planned, but suggests at least,
that hemorrhage (that is, blood source) is not likely the
main source of LPA after TBI. One could further argue
against the blood source of the LPA-pulse in that the
concentration of LPA in CSF (approximately 2 μM for
mouse) is much higher than the 50 to 100 nM levels
typically observed in plasma [23]. One would suspect
that the plasma source of LPA would be diluted even
more when mixed with the CSF. An additional argument
against plasma as the source of the LPA-pulse is the
finding that LPC levels are in the range of 50 nM for
CSF (and do not change after TBI), while LPC levels are
in the 50 to 100 microM range in the plasma [23], indicating that the ratio of LPA/LPC is quite different between plasma and CSF, including after TBI.
In vitro studies using the Kinetic Exclusion Assay
(KinExA) [24] (Table 2) demonstrate that the anti-LPA
mAbs recognize all relevant LPA species, particularly the
unusual 18:0 and 16:0 LPAs that are abundant in the
CSF of injured mice and humans.
The apparent affinities of the B3 mAb for the various
LPA species are at a minimum of four times higher but
typically two to three orders of magnitude higher than
the affinities enjoyed by the LPA receptors as reported
in the literature, affinities reported to be between approximately 60 and 800 nM [25,26]. This is a complicated issue as each receptor has different affinities for
the various LPAs, as they are not all equally potent in
activating a particular receptor. Despite this, our antibodies are potent in vitro with regard to binding up all
relevant LPA species. Moreover, one might argue that
the important proof of potency is that our antibodies
demonstrate in vivo efficacy reported here and in mitigating SCI [5].
It could be argued that the use of a LPA-neutralizing
antibody could provide an alternate approach to reducing
upregulated LPA signaling. Neutralizing extracellular LPA
Table 2 KinExA measurements of the apparent
equilibrium dissociation constants (KD, app) for B3
binding individual LPA species
LPA species

KD, app (nM)

95% CI (nM)

16:0

0.88

0.65, 1.1

18:0

14

12, 16

18:1

3.1

2.6, 3.5

18:2

1.5

1.3, 1.7

20:4

5.7

5.3, 6.0

KinExA data were analyzed using the standard analysis method with drift
correction. All analysis carried out using KinExA Pro software.

with an antibody would silence all of the LPA receptors
and ion channel targets, and would not discriminate on
LPA synthesized by a variety of enzymatic sources, The
disadvantages of antibody therapeutics is the high cost of
the drug product, plus the drug must have access to the
tissue compartment where the target (that is, LPA) is dysregulated. Fortunately for antibody therapeutics in the TBI
context, the BBB of the TBI patient is usually permeable
to large proteins like therapeutic antibodies during the
critical-care period where salvaging of damaged nerve tissue would be attempted.
We have recently humanized and affinity-matured the
anti-LPA mAb by grafting the murine CDR regions on
to a human IgGκ1 framework. This preclinical drug candidate, LT3114, retains the specificity for key LPA isoforms, plus it exhibits high affinity enjoyed by the
murine B3 mAb. The humanized antibody could serve
as a potential therapeutic agent for neurotrauma by limiting the initial injury and, at the same time, reducing
dangerous inflammatory processes, possibly closing
down the permeabilized BBB while stimulating regenerative processes. Thus, neutralizing extracellular LPA with
the humanized mAbs could be the first therapeutic
agent that mitigates both early and late phases of neurotrauma with resulting potential beneficial outcomes in
rehabilitation and functional recovery for patients.
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